S
Scout Bio
Scout Bio is a Health care company
About Scout Bio
Scout Bio is a pioneering company in the veterinary medicine sector, leveraging advancements in human genetic research to develop cutting-edge treatments for companion animals. The company focuses on creating one-time gene therapies and protein therapeutics that offer long-lasting and targeted solutions for various animal health issues. Scout Bio primarily serves pet owners who seek advanced medical treatments for their pets, addressing conditions such as anemia due to chronic kidney disease in cats. Operating within the veterinary pharmaceutical market, Scout Bio's business model revolves around the development and commercialization of these innovative therapies. Revenue is generated through the sale of these specialized treatments, which are designed to improve the quality of life for pets and meet the growing demand for advanced veterinary care. The company has secured significant financing, including a recent $20 million investment, to advance its pipeline of therapies. Scout Bio's leadership team includes experienced professionals from the life sciences sector, further strengthening its position in the market.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Philadelphia, United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 71.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Synthetic Biology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Scout Bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jan 2024 | $0 | — | Ceva Sante Animale | ↗ |
| SERIES BOther financing | Oct 2021 | $33M | $132M | Adage Capital · OrbiMed · Frazier Healthcare Partners · Digitalis Ventures | — |
Growth signals
Latest recorded traffic for Scout Bio is 1.8K monthly website visits, up 5.9% over the last three months. Scout Bio's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Correlation Ventures
RiverVest Venture Partners
Greenspring Associates
Frazier Healthcare Partners
Digitalis Ventures
Adage Capital
OrbiMed
Other known investors2 additional known investors
Ceva Sante Animale
University of Pennsylvania
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Scout Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Scout Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.